Literature DB >> 26419780

Illness intrusiveness and subjective well-being in patients with glioblastoma.

Kim Edelstein1,2,3, Linda Coate4, Christine Massey5, Natalie C Jewitt6, Warren P Mason6,7,8, Gerald M Devins9,10.   

Abstract

Glioblastoma (GBM) is the most common adult CNS malignancy but its impact on quality of life (QOL) is poorly understood. In other patient populations, illness intrusiveness (the extent to which disease and treatment disrupts valued activities and interests) is associated with low subjective well-being, after controlling for disease and treatment variables. In this cross-sectional cohort study, we examined the relations among illness intrusiveness, disease burden, and subjective well-being in GBM. 73 GBM patients completed validated self-report measures of depression, positive affect, illness intrusiveness, and health-related QOL. Responses were compared to data from six other cancer groups using repeated measures analyses of variance. Hierarchical multiple-regression analyses tested the hypothesis that illness intrusiveness accounts for well-being after controlling for the effects of disease burden. GBM patients reported less positive affect, more depression, and more illness intrusiveness than people with other cancers. Illness intrusiveness correlated with depression and (low) positive affect. Associations among cancer symptoms, depression, and positive affect decreased when illness intrusiveness was added to regression equations. Good performance status and high cancer-symptom burden were associated with illness intrusiveness and depression. GBM patients report greater distress, lower positive affect, and more illness intrusiveness than people with other cancers. Subjective well-being is mediated in part by illness intrusiveness in this population. In addition to medical treatment, efforts to help patients remain engaged in valued activities and interests may help preserve QOL after the diagnosis of a GBM.

Entities:  

Keywords:  Brain tumor; Disease burden; GBM; High grade glioma; Mood; Psychosocial; Quality of life

Mesh:

Year:  2015        PMID: 26419780     DOI: 10.1007/s11060-015-1943-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Health-related quality of life in patients with glioblastoma: a randomised controlled trial.

Authors:  Martin J B Taphoorn; Roger Stupp; Corneel Coens; David Osoba; Rolf Kortmann; Martin J van den Bent; Warren Mason; René O Mirimanoff; Brigitta G Baumert; Elizabeth Eisenhauer; Peter Forsyth; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2005-12       Impact factor: 41.316

2.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

Review 3.  Cognitive dysfunction after chemotherapy for breast cancer.

Authors:  Kim Edelstein; Lori J Bernstein
Journal:  J Int Neuropsychol Soc       Date:  2014-03-24       Impact factor: 2.892

4.  Brain cancer and sexual health: a case report.

Authors:  Michael L Krychman; Alison Amsterdam; Jeanne Carter; Mercedes Castiel; Lisa DeAngelis
Journal:  Palliat Support Care       Date:  2004-09

5.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

Authors:  T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

6.  Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Authors:  Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-02-11       Impact factor: 4.130

7.  Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.

Authors:  Jeong-Heon Lee; Tae-Young Jung; Shin Jung; In-Young Kim; Woo-Youl Jang; Kyung-Sub Moon; Eun-Hui Jeong
Journal:  J Clin Neurosci       Date:  2013-01-11       Impact factor: 1.961

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Robert Grant; Ruth Garside; Gabriel Rogers; Margaret Somerville; Ken Stein
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

10.  Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.

Authors:  Stacey Snyder; Frederick W Foley; Eileen Farrell; Meghan Beier; Vance Zemon
Journal:  J Neurol Sci       Date:  2013-07-10       Impact factor: 3.181

View more
  10 in total

Review 1.  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Authors:  Dina Randazzo; Katherine B Peters
Journal:  CNS Oncol       Date:  2016-07-11

Review 2.  Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature.

Authors:  Luke Mugge; Tarek R Mansour; Megan Crippen; Yasaman Alam; Jason Schroeder
Journal:  Neurosurg Rev       Date:  2018-08-09       Impact factor: 3.042

3.  The interplay among psychological distress, the immune system, and brain tumor patient outcomes.

Authors:  Sebastian Otto-Meyer; Jan Lumibao; Eugene Kim; Erik Ladomersky; Lijie Zhai; Kristen L Lauing; Denise M Scholtens; Frank Penedo; Christina Amidei; Rimas V Lukas; Derek A Wainwright
Journal:  Curr Opin Behav Sci       Date:  2019-02-26

4.  Association between depression and brain tumor: a systematic review and meta-analysis.

Authors:  Jing Huang; Chao Zeng; Juxiong Xiao; Danwei Zhao; Hui Tang; Haishan Wu; Jindong Chen
Journal:  Oncotarget       Date:  2017-08-03

5.  Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives.

Authors:  Pernilla Ståhl; Boglarka Fekete; Ingela Henoch; Anja Smits; Asgeir S Jakola; Bertil Rydenhag; Anneli Ozanne
Journal:  J Neurooncol       Date:  2020-09-09       Impact factor: 4.130

Review 6.  Palliative Care in High-Grade Glioma: A Review.

Authors:  Rita C Crooms; Nathan E Goldstein; Eli L Diamond; Barbara G Vickrey
Journal:  Brain Sci       Date:  2020-10-13

7.  Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study.

Authors:  Marissa Barbaro; Craig D Blinderman; Fabio M Iwamoto; Teri N Kreisl; Mary R Welch; Yazmin Odia; Laura E Donovan; Adela E Joanta-Gomez; Katharine A Evans; Andrew B Lassman
Journal:  Neurology       Date:  2021-11-18       Impact factor: 9.910

8.  Quality of life in patients with glioblastoma and their relatives.

Authors:  Pernilla Ståhl; Ingela Henoch; Anja Smits; Bertil Rydenhag; Anneli Ozanne
Journal:  Acta Neurol Scand       Date:  2022-04-26       Impact factor: 3.915

9.  Characteristics of health-related quality of life and related factors in patients with brain tumors treated with rehabilitation therapy.

Authors:  Takahiro Watanabe; Shinichi Noto; Manabu Natsumeda; Shinji Kimura; Satoshi Tabata; Fumie Ikarashi; Mayuko Takano; Yoshihiro Tsukamoto; Makoto Oishi
Journal:  J Patient Rep Outcomes       Date:  2022-09-06

10.  Association of Low-Grade Glioma Diagnosis and Management Approach with Mental Health Disorders: A MarketScan Analysis 2005-2014.

Authors:  Debarati Bhanja; Djibril Ba; Kyle Tuohy; Hannah Wilding; Mara Trifoi; Varun Padmanaban; Guodong Liu; Michael Sughrue; Brad Zacharia; Douglas Leslie; Alireza Mansouri
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.